- 专利标题： SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS
-
申请号： US15703056申请日： 2017-09-13
-
公开(公告)号： US20180072667A1公开(公告)日： 2018-03-15
- 发明人: Steffen Gaali , Felix Hausch , Alexander Kirschner , Xixi Feng , Andreas Bracher , Gerd Ruehter
- 申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
- 优先权： EP13185247.7 20130919; EP13196561.8 20131210; EP14151510.6 20140116
- 主分类号： C07D207/16
- IPC分类号： C07D207/16 ; G06F19/16 ; C12N9/90 ; C07D211/78 ; C07D401/14 ; C07D279/12 ; C07D405/12 ; C07D401/12 ; C07D211/60
摘要：
The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.
公开/授权文献
信息查询
